$0.00
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Invivyd Inc (IVVD)
| -63.6 | 47.2 | -18.2 | -12.6 | -21.5 | -49.4 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Invivyd Inc (IVVD)
| 457.4 | -88.6 | 162.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Invivyd Inc (IVVD)
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart,... a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut. Read more
-
CEO & Director
Mr. David Hering M.B.A.
-
CEO & Director
Mr. David Hering M.B.A.
-
Headquarters
New Haven, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Invivyd Inc (IVVD)
What is the current share price of Invivyd Inc (IVVD) Today?
The share price of Invivyd Inc (IVVD) is $0.90 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Invivyd Inc (IVVD) has given a return of -21.49% in the last 3 years.
What is the current PB & PE ratio of Invivyd Inc (IVVD)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-8.10 |
1.76 |
2024 |
-0.31 |
0.78 |
2023 |
-2.18 |
2.44 |
2022 |
-0.68 |
0.46 |
2021 |
-1.36 |
0.55 |
What is the 52 Week High and Low of Invivyd Inc (IVVD)?
The 52-week high and low of Invivyd Inc (IVVD) are Rs 3.07 and Rs 0.53 as of 28-Aug-2026.
What is the market cap of Invivyd Inc (IVVD)?
Invivyd Inc (IVVD) has a market capitalisation of $ 294 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Invivyd Inc (IVVD)?
Before investing in Invivyd Inc (IVVD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.